Tags : Large

MorphoSys Reports Submission of Tafasitamab’s BLA to the US FDA

Shots: The BLA submission is based on L-MIND P-II trial data results assessing Tafasitamab + lenalidomide in patients with r/r DLBCL and retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received Tafasitamab + lenalidomide vs lenalidomide monothx Re-MIND has met its 1EPs and has shown improved ORR of the […]Read More

JHL Biotech Reports Randomization of Patients in P-III Study of

Shots:   The study involves assessing of JHL1101 + CHOP (J-CHOP) vs rituximab + CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma  Post P-III Study of JHL1101 and combination therapy, JHL Biotech plans to conduct PK study in RA patients in EU JHL1101 (biosimilar to Rituximab) is a mAb targeting CD20 cells, for […]Read More